A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid β in the brain in a transgenic model of Alzheimer disease

Journal of Biological Chemistry

Volumn 290, Issue 4, 2015, Pages 1966-1978

  Hori, Yukiko ^a   Takeda, Shuko ^a   Cho, Hansang ^b   Wegmann, Susanne ^a   Shoup, Timothy M ^a   Takahashi, Kazue ^a   Irimia, Daniel ^b   Elmaleh, David R ^a   Hyman, Bradley T ^a   Hudry, Eloise ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GLYCOPROTEINS; MONOMERS; NEURODEGENERATIVE DISEASES; OLIGOMERS; PROTEINS; SODIUM;

ALZHEIMER DISEASE; AMYLOID BETAS; FOOD AND DRUG ADMINISTRATION; HALF LIVES; HIGHER-ORDER; INTRAPERITONEALLY; THERAPEUTIC AGENTS; TRANSGENIC MODELS;

DISEASE CONTROL;

AMYLOID BETA PROTEIN; CROMOGLYCATE DISODIUM; DIMETHYL SULFOXIDE; AMYLOID BETA-PROTEIN (1-42); FISETIN; FLAVONOID; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN AGGREGATION; PROTEIN METABOLISM; TRANSGENIC MOUSE; ANIMAL; BRAIN; CELL CULTURE; CHEMISTRY; DISEASE MODEL; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; METABOLISM; MICROGLIA; TRANSMISSION ELECTRON MICROSCOPY; UNITED STATES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CELLS, CULTURED; CROMOLYN SODIUM; DISEASE MODELS, ANIMAL; DRUG APPROVAL; FLAVONOIDS; HUMANS; MICE; MICE, TRANSGENIC; MICROGLIA; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDE FRAGMENTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84961291728     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.586602     Document Type: Article

References (51)

1. Anand, P., and Singh, B. (2013) A review on cholinesterase inhibitors for Alzheimer's disease. Arch. Pharm. Res. 36, 375-399
2. Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R., Watkins, W. E., Xu, Y., and Murthy, A. K. (2009) Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 72, 1555-1561
3. Cummings, J. L. (2004) Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev. Neurol. Dis. 1, 60-69
4. Selkoe, D. J. (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid β-protein. J. Alzheimers Dis. 3, 75-80
5. Gouras, G. K., Tampellini, D., Takahashi, R. H., and Capetillo-Zarate, E. (2010) Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 119, 523-541
6. Wu, H. Y., Hudry, E., Hashimoto, T., Kuchibhotla, K., Rozkalne, A., Fan, Z., Spires-Jones, T., Xie, H., Arbel-Ornath, M., Grosskreutz, C. L., Bacskai, B. J., and Hyman, B. T. (2010) Amyloid β induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J. Neurosci. 30, 2636-2649
7. Reddy, P. H., and Beal, M. F. (2008) Amyloid β, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med. 14, 45-53
8. Spires, T. L., Meyer-Luehmann, M., Stern, E. A., McLean, P. J., Skoch, J., Nguyen, P. T., Bacskai, B. J., and Hyman, B. T. (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25, 7278-7287
9. Götz, J., Schild, A., Hoerndli, F., and Pennanen, L. (2004) Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int. J. Dev. Neurosci. 22, 453-465
10. Kurt, M. A., Davies, D. C., Kidd, M., Duff, K., and Howlett, D. R. (2003) Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol. Dis. 14, 89-97
11. Selkoe, D. J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766
12. Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Selkoe, D. J. (1992) Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672-674
13. Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., Takuma, H., Kuwano, R., Imagawa, M., Ataka, S., Wada, Y., Yoshioka, E., Nishizaki, T., Watanabe, Y., and Mori, H. (2008) A new amyloid β variant favoring oligomerization in Alzheimer's-type dementia. Ann. Neurol. 63, 377-387
14. Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., and Stefansson, K. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99
15. Di Fede, G., Catania, M., Morbin, M., Rossi, G., Suardi, S., Mazzoleni, G., Merlin, M., Giovagnoli, A. R., Prioni, S., Erbetta, A., Falcone, C., Gobbi, M., Colombo, L., Bastone, A., Beeg, M., Manzoni, C., Francescucci, B., Spagnoli, A., Cantú, L., Del Favero, E., Levy, E., Salmona, M., and Tagliavini, F. (2009) A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 323, 1473-1477
16. Ertekin-Taner, N., Graff-Radford, N., Younkin, L. H., Eckman, C., Baker, M., Adamson, J., Ronald, J., Blangero, J., Hutton, M., and Younkin, S. G. (2000) Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 290, 2303-2304
17. Hardy, J., and Selkoe, D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356
18. Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., and Bateman, R. J. (2010) Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 330, 1774
19. Takeda, S., Hashimoto, T., Roe, A. D., Hori, Y., Spires-Jones, T. L., and Hyman, B. T. (2013) Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB J. 27, 3239-3248
20. Townsend, M., Shankar, G. M., Mehta, T., Walsh, D. M., and Selkoe, D. J. (2006) Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol. 572, 477-492
21. Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., Nishitsuji, K., Ito, K., Shimada, H., Lambert, M. P., Klein, W. L., and Mori, H. (2010) A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal Tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci. 30, 4845-4856
22. Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., Hyman, B. T., and Spires-Jones, T. L. (2009) Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U.S.A. 106, 4012-4017
23. Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., Regan, C. M., Walsh, D. M., Sabatini, B. L., and Selkoe, D. J. (2008) Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842
24. Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., and Ashe, K. H. (2006) A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357
25. Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2005) Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84
26. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539
27. Akaishi, T., Morimoto, T., Shibao, M., Watanabe, S., Sakai-Kato, K., Utsunomiya-Tate, N., and Abe, K. (2008) Structural requirements for the flavonoid fisetin in inhibiting fibril formation of amyloid β protein. Neurosci. Lett. 444, 280-285
28. Ushikubo, H., Watanabe, S., Tanimoto, Y., Abe, K., Hiza, A., Ogawa, T., Asakawa, T., Kan, T., and Akaishi, T. (2012) 3,3′,4′,5,5′-Pentahydroxyflavone is a potent inhibitor of amyloid β fibril formation. Neurosci Lett 513, 51-56
29. Leza, J. C., Lizasoain, I., San-Martín-Clark, O., and Lorenzo, P. (1995) Morphine-induced changes in cerebral and cerebellar nitric oxide synthase activity. Eur. J. Pharmacol. 285, 95-98
30. San-Martín-Clark, O., Cuéllar, B., De Alba, J., Leza, J. C., and Lorenzo, P. (1995) Changes induced by sodium cromoglycate in brain catecholamine turnover in morphine dependent and abstinent mice. Psychopharmacology 118, 347-353
31. Hori, Y., Hashimoto, T., Wakutani, Y., Urakami, K., Nakashima, K., Condron, M. M., Tsubuki, S., Saido, T. C., Teplow, D. B., and Iwatsubo, T. (2007) The Tottori (D7N) and English (H6R) familial Alzheimer disease mutations accelerate Aβ fibril formation without increasing protofibril formation. J. Biol. Chem. 282, 4916-4923
32. Hashimoto, T., Adams, K. W., Fan, Z., McLean, P. J., and Hyman, B. T. (2011) Characterization of oligomer formation of amyloid-β peptide using a split-luciferase complementation assay. J. Biol. Chem. 286, 27081-27091
33. Wegmann, S., Medalsy, I. D., Mandelkow, E., and Müller, D. J. (2013) The fuzzy coat of pathological human Tau fibrils is a two-layered polyelectrolyte brush. Proc. Natl. Acad. Sci. U.S.A. 110, E313-E321
34. Cho, H., Hashimoto, T., Wong, E., Hori, Y., Wood, L. B., Zhao, L., Haigis, K. M., Hyman, B. T., and Irimia, D. (2013) Microfluidic chemotaxis platform for differentiating the roles of soluble and bound amyloid-β on microglial accumulation. Sci. Rep. 3, 1823
35. Borchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., and Sisodia, S. S. (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945
36. Hashimoto, T., Wakabayashi, T., Watanabe, A., Kowa, H., Hosoda, R., Nakamura, A., Kanazawa, I., Arai, T., Takio, K., Mann, D. M., and Iwatsubo, T. (2002) CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J. 21, 1524-1534
37. Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K. W., Takeda, S., Banerji, A. O., Mitani, A., Joyner, D., Thyssen, D. H., Bacskai, B. J., Frosch, M. P., Spires-Jones, T. L., Finn, M. B., Holtzman, D. M., and Hyman, B. T. (2012) Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J. Neurosci. 32, 15181-15192
38. Takeda, S., Sato, N., Ikimura, K., Nishino, H., Rakugi, H., and Morishita, R. (2011) Novel microdialysis method to assess neuropeptides and large molecules in free-moving mouse. Neuroscience 186, 110-119
39. Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., DeMattos, R. B., and Holtzman, D. M. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23, 8844-8853
40. Cockcroft, D. W. (1999) Pharmacologic therapy for asthma: overview and historical perspective. J. Clin. Pharmacol. 39, 216-222
41. Storms, W., and Kaliner, M. A. (2005) Cromolyn sodium: fitting an old friend into current asthma treatment. J. Asthma 42, 79-89
42. Ratner, P. H., Ehrlich, P. M., Fineman, S. M., Meltzer, E. O., and Skoner, D. P. (2002) Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin. Proc. 77, 350-354
43. Maher, P., Akaishi, T., and Abe, K. (2006) Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc. Natl. Acad. Sci. U.S.A. 103, 16568-16573
44. Ishige, K., Schubert, D., and Sagara, Y. (2001) Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic. Biol. Med. 30, 433-446
45. Kim, H., Park, B. S., Lee, K. G., Choi, C. Y., Jang, S. S., Kim, Y. H., and Lee, S. E. (2005) Effects of naturally occurring compounds on fibril formation and oxidative stress of β-amyloid. J. Agric. Food Chem. 53, 8537-8541
46. Sciarretta, K. L., Gordon, D. J., and Meredith, S. C. (2006) Peptide-based inhibitors of amyloid assembly. Methods Enzymol. 413, 273-312
47. Ma˚nsson, C., Arosio, P., Hussein, R., Kampinga, H. H., Hashem, R. M., Boelens, W. C., Dobson, C. M., Knowles, T. P., Linse, S., and Emanuelsson, C. (2014) Interaction of the molecular chaperone DNAJB6 with growing amyloid-β 42 (Aβ42) aggregates leads to sub-stoichiometric inhibition of amyloid formation. J. Biol. Chem. 289, 31066-31076
48. Abraham, J. N., Kedracki, D., Prado, E., Gourmel, C., Maroni, P., and Nardin, C. (2014) Effect of the interaction of the amyloid β (1-42) peptide with short single-stranded synthetic nucleotide sequences: morphological characterization of the inhibition of fibrils formation and fibrils disassembly. Biomacromolecules 15, 3253-3258
49. Quitschke, W. W., Steinhauff, N., and Rooney, J. (2013) The effect of cyclodextrin-solubilized curcuminoids on amyloid plaques in Alzheimer transgenic mice: brain uptake and metabolism after intravenous and subcutaneous injection. Alzheimers Res. Ther. 5, 16
50. Currais, A., Prior, M., Dargusch, R., Armando, A., Ehren, J., Schubert, D., Quehenberger, O., and Maher, P. (2014) Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice. Aging Cell 13, 379-390
51. Kim, D. S., Kim, J. Y., and Han, Y. (2012) Curcuminoids in neurodegenerative diseases. Recent Pat. CNS Drug Discov. 7, 184-204